Skip to content
10-Q

Quarterly Report

ANADYS PHARMACEUTICALS INC

0001193125-11-299984

← back to feed
Filed
Nov 7, 2011 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2011 · Oct 28, 2011 57.44M sh
Capex Q3 2011 · Sep 30, 2011 $30K
Capex Q3 2011 · Sep 30, 2010 $7K
Operating Cash Flow Q3 2011 · Sep 30, 2011 −$18.48M
Operating Cash Flow Q3 2011 · Sep 30, 2010 −$12.78M
Cash And Equivalents Q3 2011 · Sep 30, 2011 $1.08M
Cash And Equivalents Q3 2011 · Dec 31, 2010 $7.62M
Cash And Equivalents Q3 2011 · Sep 30, 2010 $1.89M
Cash And Equivalents Q3 2011 · Dec 31, 2009 $4.5M
Stockholders Equity Q3 2011 · Sep 30, 2011 $12.8M
Stockholders Equity Q3 2011 · Dec 31, 2010 $34.67M
Current Liabilities Q3 2011 · Sep 30, 2011 $7.37M
Current Liabilities Q3 2011 · Dec 31, 2010 $4.85M
Current Assets Q3 2011 · Sep 30, 2011 $20.07M
Current Assets Q3 2011 · Dec 31, 2010 $39.3M
Total Assets Q3 2011 · Sep 30, 2011 $20.17M
Total Assets Q3 2011 · Dec 31, 2010 $39.54M
Sga Expense Q3 2011 · Sep 30, 2011 $1.67M
Sga Expense Q3 2011 · Sep 30, 2011 $4.74M
Sga Expense Q3 2011 · Sep 30, 2010 $1.51M
Sga Expense Q3 2011 · Sep 30, 2010 $4.75M
Rd Expense Q3 2011 · Sep 30, 2011 $7.99M
Rd Expense Q3 2011 · Sep 30, 2011 $20M
Rd Expense Q3 2011 · Sep 30, 2010 $2.49M
Rd Expense Q3 2011 · Sep 30, 2010 $9.27M
Net Income Q3 2011 · Sep 30, 2011 −$9.14M
Net Income Q3 2011 · Sep 30, 2011 −$23.21M
Net Income Q3 2011 · Sep 30, 2010 −$4.74M
Net Income Q3 2011 · Sep 30, 2010 −$13.92M